1130: Measurement of Minimal Residual Disease Using Real Time PCR in Canine Lymphoma

Grant Status: Closed

Grant Amount: $83,259
Susan E. Lana, DVM; Colorado State University
January 1, 2009 - June 30, 2011

Sponsor(s): American Bloodhound Club, American Bullmastiff Association, American Spaniel Club Foundation, Bernese Mountain Dog Club of America, Briard Club of America Health & Education Trust, Collie Health Foundation, English Springer Spaniel Field Trial Association Foundation, Flat-Coated Retriever Foundation, Golden Retriever Foundation, Gordon Setter Club of America, Health & Rescue Foundation of the Petit Basset Griffon Vendeen Club of America, Jeffrey Pepper, Mastiff Club of America, National Amateur Retriever Club, Newfoundland Club of America Charitable Trust, TarTan Gordon Setter Club, Tibetan Terrier Club of America/Tibetan Terrier Health & Welfare Foundation, United States Australian Shepherd Association

Breed(s): -All Dogs
Research Program Area: Oncology - Lymphoma
Donate to Support this Research Program Area

Project Summary

Most canine patients treated for lymphoma (>80%) will achieve complete remission. Cures, however, are rare and pets relapse and die of their disease. The cause of this relapse is the presence of residual malignant cells that eventually grow and become clinically detectable. With the advent of more sensitive molecular techniques the measurement of minimal residual disease (MRD) could be incorporated into clinical case management to optimize treatment strategies; improve patient outcome, and to gain additional insight into the basic biology of lymphoma. To date serial blood samples from 68 canine patients with lymphoma undergoing treatment taken at a variety of time points have been collected. Concerning follow up of those patients, 56 have died of their lymphoma, 3 have died of other non-cancer causes. Nine patients are still alive as of 9/26/11. Of those 9, 4 had come out of remission and completed sample collection, 5 are still in remission but we have stopped sample collection in those patients. A total of 555 samples have been collected from these 68 patients with an average number of samples per patient of 8. Immunophenotype and treatment characteristics of these 68 patients are as follows; 50 are B cell, 16 are T cell, one has both markers, and one is pending. From a treatment standpoint, 37 dogs received a multiple drug chemotherapy protocol (35= CHOP, 2 COP), 26 received doxorubicin single agent therapy, and 5 received investigational drugs as part of a clinical trial. Extraction of DNA, development of patient specific primers, and analysis of quantitative MRD is ongoing. All patient information has been collected and complied at this point and will be correlated with molecular assay results when they become available. With this information we will answer the following questions: Does the level of molecular disease burden at the time of diagnosis and at the end of chemotherapy (i.e. the magnitude of decrease) correlate with remission length and overall survival. We hypothesize that it will.


Johnston, S. A., Thamm, D. H., & Legutki, J. B. (2014). The immunosignature of canine lymphoma: Characterization and diagnostic application. BMC Cancer, 14(1).https://doi.org/10.1186/1471-2407-14-657

Thomas, R., Borst, L., Rotroff, D., Motsinger-Reif, A., Lindblad-Toh, K., Modiano, J. F., & Breen, M. (2014). Genomic profiling reveals extensive heterogeneity in somatic DNA copy number aberrations of canine hemangiosarcoma. Chromosome Research, 22(3), 305–319. https://doi.org/10.1007/s10577-014-9406-z

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Connect With Us:
Get Canine Health News:
Please leave this field empty

© 2018 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.

Powered by Blackbaud
nonprofit software